Obesity Medicine

ACOG 2025: Johanna Finkle, MD, shares strategies to start weight conversations with patients and build clinician confidence in counseling and treatment options.

Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.

Your daily dose of the clinical news you may have missed.

Phenomix will showcase new data on prediction of adverse events to GLP-1 RA therapy, a new obesity sub-phenotype, and approaches to improve surgical outcomes.

Northstrive Biosciences received positive FDA feedback for its IND application for EL-22, a probiotic-based treatment for obesity.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

ACP 2025: GLP-1 medications are advancing obesity care, but lifestyle changes and bariatric surgery remain key components. Laura Davisson, MD, discusses how to personalize treatment strategies.

Following a Mediterranean-style diet and a prescribed regimen of physical activity was significantly protective of BMD, particularly at the lumbar level, over 3 years.

The FDA and Novo Nordisk are urging health care professionals to check semaglutide (Ozempic) injection 1 mg lot PAR0362 with serials starting 51746517.

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Loss of lean muscle mass along with fat mass is a concerning side effect of the incretin-based antiobesity medications, making the new study results encouraging.

ACP 2025: Laura Davisson, MD, outlines how PCPs can navigate GLP-1 medication coverage issues and why to consider recent cash-pay options.

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

Your daily dose of the clinical news you may have missed.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Your daily dose of the clinical news you may have missed.

Data from the phase 2 VENTURE-Oral Dosing Trial of VK2735 is expected in the second half of the year, the company said.

The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.

Your daily dose of the clinical news you may have missed.

The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.